As biopharma and healthcare companies face a rapidly shifting regulatory environment, marketing and advisory firm Avalere ...
Built into the 2026 guidance is a $1.5 billion decline in sales of its COVID products—from an estimated $6.5 billion this ...
Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it ...
With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback